Core Insights - Sensei Biotherapeutics, Inc. is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients [3] - The company will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 11, 2025 [1] - Sensei's lead product candidate is solnerstotug, designed to block the VISTA checkpoint selectively in the tumor microenvironment [3] Company Overview - Sensei Biotherapeutics operates through its TMAb™ platform, which develops conditionally active therapeutics to target immunosuppressive signals in tumors [3] - The company's approach aims to activate T cells against tumors by selectively disabling immunosuppressive mechanisms [3] Event Details - John Celebi, President and CEO of Sensei, will present at the conference virtually at 10:40 a.m. ET [1] - A webcast of the presentation will be available on the company's website for approximately 90 days post-event [2]

Company Overview - Sensei Biotherapeutics, Inc. is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients [3] - The company utilizes its TMAb™ platform to create conditionally active therapeutics that target the tumor microenvironment, aiming to enhance T cell activity against tumors [3] Product Development - Sensei's lead product candidate is solnerstotug, an antibody designed to block the VISTA checkpoint selectively in the low pH tumor microenvironment, which is crucial for T cell activation [3] Upcoming Events - John Celebi, President and CEO of Sensei Biotherapeutics, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 10:40 a.m. ET [1] - A webcast of the presentation will be available on the company's website, with a replay accessible for approximately 90 days post-event [2]

Core Insights - Sensei Biotherapeutics is advancing its lead program, solnerstotug (SNS-101), which targets the immune checkpoint VISTA, with expectations for significant clinical data updates in 2025 [1][2][4] Company Overview - Sensei Biotherapeutics is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients, utilizing its TMAb™ platform to create conditionally active therapeutics [4][5] Product Development - Solnerstotug (SNS-101) is designed to selectively target VISTA within the tumor microenvironment, which is associated with low survival rates in various cancer types [3][4] - The company is conducting a multi-center Phase 1/2 clinical trial to evaluate solnerstotug's safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy, both as a monotherapy and in combination with Regeneron's PD-1 inhibitor Libtayo® [4][5] Clinical Trial Progress - As of January 1, 2025, 45 patients have been enrolled in the dose expansion portion of the trial, with an expected total of approximately 60 patients by the end of Q1 2025 [5] - The company anticipates reporting data from evaluable patients in Q2 2025, including follow-up data from dose escalation cohorts [5] Financial Position - Sensei Biotherapeutics has a cash runway projected into the second quarter of 2026, allowing for the advancement of solnerstotug through the completion of the Phase 1 portion of the study [2][5]

Financial Performance - The company reported a net loss of $22.4 million for the nine months ended September 30, 2024, compared to a net loss of $26.7 million for the same period in 2023, indicating a decrease in losses of approximately 16.1%[69] - The company reported a net loss of $22.4 million for the nine months ended September 30, 2024, an improvement from a net loss of $26.7 million in the same period of 2023, reflecting a decrease of $4.3 million[88] - Net cash used in operating activities was $18.9 million for the nine months ended September 30, 2024, compared to $25.9 million in the same period of 2023, indicating improved cash flow management[90] - The company incurred net cash used in financing activities of $0.6 million for the nine months ended September 30, 2024, a significant decrease from $10.7 million in the same period of 2023[93] - Other income decreased to $2.0 million for the nine months ended September 30, 2024, down from $2.2 million in 2023, primarily due to a decrease in interest income[87] Expenses - Research and development expenses increased to $4.6 million for the three months ended September 30, 2024, from $3.8 million in the same period of 2023, reflecting an increase of 21.3%[80] - General and administrative expenses decreased to $3.2 million for the three months ended September 30, 2024, down from $3.9 million in the same period of 2023, a reduction of 17.9%[81] - Research and development expenses increased to $14.1 million for the nine months ended September 30, 2024, up from $13.8 million in the same period of 2023, reflecting a $0.3 million rise primarily due to higher clinical trial costs[84] - General and administrative expenses decreased significantly to $10.2 million for the nine months ended September 30, 2024, down from $15.1 million in 2023, a reduction of $4.9 million attributed to lower external professional services and personnel costs[86] - The company anticipates significant increases in expenses related to ongoing clinical trials, regulatory approvals, and commercialization efforts[69] - The company anticipates an increase in expenses related to ongoing research and development activities, including clinical trials and regulatory approvals for product candidates[98] Funding and Capital - The company has raised an aggregate of $123.4 million from private placements and $138.5 million from its IPO in February 2021, totaling $261.9 million in gross proceeds[69] - As of September 30, 2024, the company had cash, cash equivalents, and marketable securities totaling $47.0 million, with an accumulated deficit of $254.3 million[88] - The company expects its existing cash and marketable securities to fund operations into the second quarter of 2026, based on current assumptions[100] - Net cash provided by investing activities was $25.6 million for the nine months ended September 30, 2024, primarily due to $52.5 million in maturities of short-term investments[91] Clinical Development - The company currently has one investigational product candidate, SNS-101, in clinical development, with a Phase 1/2 trial initiated in May 2023[67] - Patient enrollment for the dose expansion portion of the Phase 1/2 study of SNS-101 is expected to reach an aggregate of 50 to 70 patients[67] - The company plans to decrease operating expenses by approximately 46% through workforce reduction and closing its research site in Rockville, Maryland[67] Company Classification and Reporting - The company may take advantage of exemptions until the last day of the fiscal year following the fifth anniversary of its initial public offering, ceasing to be an emerging growth company (EGC) if annual revenue exceeds $1.235 billion or market value exceeds $700 million[107] - The company has elected not to "opt out" of the extended transition period for complying with new or revised accounting standards, meaning it will adopt new standards at the same time as private companies[108] - The company qualifies as a "smaller reporting company," with a market value of stock held by non-affiliates less than $700 million and annual revenue below $100 million in the most recently completed fiscal year[109] - As a smaller reporting company, the company may present only the two most recent fiscal years of audited financial statements in its Annual Report on Form 10-K[110] - The company has reduced disclosure obligations regarding executive compensation due to its status as a smaller reporting company[110] - The company is not required to provide quantitative and qualitative disclosures about market risk as it is classified as a smaller reporting company[111]

Clinical Development - SNS-101 Phase 1/2 dose expansion clinical data is expected in the first half of 2025[1] - The company plans to re-engage with the FDA regarding the dose optimization strategy for SNS-101 following additional data from the ongoing clinical trial[5] - Approximately half of the dose expansion study for SNS-101 has been enrolled, targeting patients with primary and acquired resistance to PD-1 inhibitors[4] Financial Performance - Cash, cash equivalents, and marketable securities were $47.0 million as of September 30, 2024, expected to fund operations into the second quarter of 2026[7] - The net loss for Q3 2024 was $7.3 million, compared to a net loss of $7.1 million in Q3 2023[9] - Total operating expenses for Q3 2024 were $7.8 million, slightly higher than $7.7 million in Q3 2023[11] Expenses - Research and Development (R&D) expenses increased to $4.6 million for Q3 2024, up from $3.8 million in Q3 2023, primarily due to higher clinical trial costs[8] - General and Administrative (G&A) expenses decreased to $3.2 million for Q3 2024, down from $3.9 million in Q3 2023, due to lower insurance premiums and outside services[9] Workforce Reduction - The company has reduced its workforce by approximately 46% to focus resources on advancing the clinical development of SNS-101[6] Asset Management - Total assets as of September 30, 2024, were $53.3 million, down from $74.4 million as of December 31, 2023[12]

Core Insights - Sensei Biotherapeutics is advancing the clinical development of SNS-101, with Phase 1/2 dose expansion clinical data expected in the first half of 2025 [1][5] - The company is undergoing organizational restructuring to focus resources on SNS-101, which includes a workforce reduction of approximately 46% [2][6] - The cash runway has been extended into the second quarter of 2026, with cash, cash equivalents, and marketable securities totaling $47.0 million as of September 30, 2024 [1][7] Clinical Development - SNS-101 is a conditionally active antibody targeting the immune checkpoint VISTA, which is associated with low survival rates in various cancer indications [3] - The Phase 1/2 clinical trial is evaluating SNS-101's safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy as both a monotherapy and in combination with Regeneron's PD1 inhibitor Libtayo® [4] - Patient enrollment in the dose expansion portion of the study is progressing, with approximately half of the study enrolled [5] Financial Performance - Research and Development (R&D) expenses for Q3 2024 were $4.6 million, an increase from $3.8 million in Q3 2023, primarily due to higher clinical trial costs [8] - General and Administrative (G&A) expenses decreased to $3.2 million in Q3 2024 from $3.9 million in Q3 2023, attributed to lower insurance premiums and outside services [9] - The net loss for Q3 2024 was $7.3 million, slightly higher than the $7.1 million loss in Q3 2023 [9][11] Corporate Updates - The company is closing its research site in Rockville, Maryland, as part of its restructuring efforts [6] - Josiah Craver was appointed as Senior Vice President, Finance, and later as the principal financial officer [6] - Sensei presented data on SNS-101 at various industry conferences, including PEGS Europe and the Society of Immunotherapy Cancer Annual Meeting [5]

BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the Company will present at two upcoming scientific conferences. Conference and Presentation Details: PEGS Europe: Protein and Antibody Engineering Summit, November 5-7, 2024, Barcelona, Spain Title: Selectively Targeting VISTA in the Tumor-Microenvironment with SNS-101, a Conditiona ...

BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in September 2024: H.C. Wainwright 26th Annual Global Investment Conference Corporate Presentation Monday, September 9, 2024, at 7:00 a.m. ET. Virtual and New York, NY 2024 Cantor Fitzgerald Global Healthcar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Biotherapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 83-1863385 (State or other ju ...

Exhibit 99.1 Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, MA – August 06, 2024 – Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the disc ...